Trial intelligence / Profile preview

Recall study of rivastigmine for ECT-induced cognitive adverse effects in late-life depression

2014-003385-24Phase 4Active

Sponsor
GGZ inGeest
Start
Mar 2015
Modality
Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
Countries
1
01

Overview

Phase 4, randomised, double-blind trial of rivastigmine in major depressive disorder (MDD) and delirium (2 arms), sponsored by GGZ inGeest. Started Mar 2015; status: active.

02

Drugs

rivastigmine
03

Conditions

major depressive disorder (MDD)delirium

Beyond the preview

Go deeper on 2014-003385-24.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on 2014-003385-24.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call